[ Back ] [ Bottom ]
91_HB1278ccr001
LRB9101304RCdvccr
1 91ST GENERAL ASSEMBLY
2 CONFERENCE COMMITTEE REPORT
3 ON HOUSE BILL 1278
4 -------------------------------------------------------------
5 -------------------------------------------------------------
6 To the President of the Senate and the Speaker of the
7 House of Representatives:
8 We, the conference committee appointed to consider the
9 differences between the houses in relation to Senate
10 Amendment No. 2 to House Bill 1278, recommend the following:
11 (1) that the House concur in Senate Amendment No. 2; and
12 (2) that House Bill 1278, AS AMENDED, be further
13 amended, with reference to the page and line numbers of
14 Senate Amendment No. 2, as follows:
15 by deleting lines 6 through 34 on page 6, all of page 7, and
16 lines 1 through 8 on page 8; and
17 on page 11, by replacing lines 23 through 25 with the
18 following:
19 "methyl benzyl ketone, phenylacetone, phenyl-2-propanone, or
20 pseudoephedrine or any of"; and
21 on page 15, line 28, by replacing "(c), (d)," with "(c),
22 (c-5), (d), (d-5),"; and
23 by deleting line 34 on page 23 and lines 1 through 8 on page
24 24; and
25 on page 24, line 29, by replacing "(Source: P.A. 90-775, eff.
26 1-1-99.)" with the following:
27 "(Source: P.A. 90-775, eff. 1-1-99.)
28 Section 99. Effective date. This Act takes effect
29 January 1, 2000.".
30 Submitted on May 26, 1999
-2- LRB9101304RCdvccr
1 s/Sen. Carl Hawkinson s/Rep. Steve Davis
2 s/Sen. Kirk Dillard s/Rep. Laren Beth Gash
3 s/Sen. Ed Petka s/Rep. Louis Lang
4 s/Sen. John Cullerton s/Rep. Richard Winkel
5 s/Sen. Ira Silverstein Rep. Patricia Lindner
6 Committee for the Senate Committee for the House
[ Top ]